Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Chemotherapy in Pediatric R/R AML
NCT03194932Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML) and acute leukemia of ambiguous lineage (ALAL), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Maximum Tolerated Combination at 28 days. Started Jul 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT03194932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194932.